|
Helping people breathe and sleep properly are the core of Sepracor's business. The company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Its marketed products include asthma drug Xopenex, insomnia therapy Lunesta, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sepracor markets its products to primary care physicians and some specialists in the US; it also has some limited operations in Canada. It has licensed international development and commercialization rights for Lunesta to Eisai and GlaxoSmithKline. Sepracor was acquired by Dainippon Sumitomo Pharma in 2009.
|
| | | Contact Information | |
Address: |
84 Waterford Dr.
Marlborough, MA 01752
| | Phone: | 508-481-6700 | | Fax: | 508-357-7499 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 1292.30 M | | Revenue Growth (1 yr): | 5.50% | | Employees (2008): | 2,400 | | Employee Growth (1 yr): | 5.40% |
|
|
Key People
| | • |
Chairman:
Timothy J. Barberich
| | • |
President, CEO, and Director:
Adrian Adams
| | • |
EVP and CFO:
Robert F. (Bob) Scumaci
|
|
|
